Prolonged sitafloxacin and doxycycline combination regimen for treating infections by highly resistant Mycoplasma genitalium
- 5 November 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (1) , 247-253
Abstract
Mycoplasma genitalium, which causes sexually transmitted diseases, is increasingly resistant to key antibiotics such as macrolides and quinolones, posing a challenge for treatment. To assess the effectiveness of prolonged sitafloxacin and doxycycline combination therapy as a new alternative treatment strategy for highly drug-resistant M. genitalium strains A prospective cohort study was conducted at the National Center for Global Health and Medicine, Tokyo, Japan, from 1 January 2020 to 31 October 2022. Patients with M. genitalium urogenital or rectal infections and those who did not receive the initial sitafloxacin monotherapy were included. Patients were administered sitafloxacin and doxycycline for 21 days as salvage therapy. M. genitalium isolates were tested for parC, gyrA and 23S rRNA resistance-associated mutations. Twenty-seven patients received the combination therapy. All M. genitalium strains available for resistance analysis had parC (24/24) and macrolide resistance-associated (25/25) mutations, and 68% (17/25) had gyrA mutations. The overall cure rate was 77.8%. For strains with concurrent parC and gyrA mutations, the cure rate was 68.8% (P = 0.053) compared with that for monotherapy (37.5%). Prolonged combination therapy is highly effective against M. genitalium strains with concurrent parC and gyrA mutations. Future research should focus on establishing the optimal treatment duration and monitoring the risk of resistance.Keywords
Funding Information
- National Center for Global Health and Medicine (20A1020, 21A1014, 23A2004)
This publication has 35 references indexed in Scilit:
- Treatment of bacterial sexually transmitted infections in Europe: gonorrhoea, Mycoplasma genitalium, and syphilisThe Lancet Regional Health - Europe, 2023
- Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data From Sexual Health Clinics in 4 US RegionsClinical Infectious Diseases, 2023
- gyrA Mutations in Mycoplasma genitalium and Their Contribution to Moxifloxacin Failure: Time for the Next Generation of Resistance-Guided TherapyClinical Infectious Diseases, 2023
- Emerging multidrug resistance contributes to treatment failure in Mycoplasma genitalium infected patients in ChinaDiagnostic Microbiology and Infectious Disease, 2022
- UAA-AAUS guideline for M. genitalium and non-chlamydial non-gonococcal urethritisJournal of Infection and Chemotherapy, 2021
- Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2020
- Resistance-Guided Antimicrobial Therapy Using Doxycycline–Moxifloxacin and Doxycycline–2.5 g Azithromycin for the Treatment of Mycoplasma genitalium Infection: Efficacy and TolerabilityClinical Infectious Diseases, 2019
- Outcomes of Resistance-guided Sequential Treatment ofMycoplasma genitaliumInfections: A Prospective EvaluationClinical Infectious Diseases, 2018
- Antimicrobial efficacies of several antibiotics against uterine cervicitis caused by Mycoplasma genitaliumJournal of Infection and Chemotherapy, 2012
- Azithromycin Treatment Failure inMycoplasma genitalium–Positive Patients with Nongonococcal Urethritis Is Associated with Induced Macrolide ResistanceClinical Infectious Diseases, 2008